Drugs & Therapy Perspectives

, Volume 35, Issue 1, pp 7–12 | Cite as

Oxymetazoline 1% cream in erythema of rosacea: a profile of its use in the USA

  • Kate McKeage
  • Katherine A. Lyseng-WilliamsonEmail author
Adis Drug Q&A


Oxymetazoline 1% cream (Rhofade) is a topical α1A-agonist approved to treat persistent facial erythema associated with rosacea in adults in the USA. It relieves the redness of affected skin by inducing vasoconstriction in the superficial skin vasculature. In clinical trials, application of oxymetazoline cream for up to 1 year was effective and generally well tolerated in rosacea patients with persistent erythema, with a low incidence of application-site reactions and rebound erythema.



This manuscript was reviewed by: R.M. Hoover, Department of Pharmacy Practice and Administrative Sciences, Idaho State University, Pocatello, ID, USA; L.H. Kircik, Icahn School of Medicine at Mount Sinai, New York, NY, USA; F. Vilchez-Márquez, Department of Dermatology, Hospital de Guadix, Guadix, Spain. During the peer review process, the marketing-authorization holder of oxymetazoline 1% cream was offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with ethical standards


The preparation of this review was not supported by any external funding.

Conflicts of interest

K. McKeage and K.A. Lyseng-Williamson are employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.


  1. 1.
    Moustafa FA, Sandoval LF, Feldman SR. Rosacea: new and emerging treatments. Drugs. 2014;74(13):1457–65.CrossRefPubMedGoogle Scholar
  2. 2.
    Gold LM, Draelos ZD. New and emerging treatments for rosacea. Am J Clin Dermatol. 2015;16(6):457–61.CrossRefPubMedGoogle Scholar
  3. 3.
    Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne and Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis. 2013;92(5):234–40.PubMedGoogle Scholar
  4. 4.
    Oge LK, Muncie HL, Phillips-Savoy AR. Rosacea: diagnosis and treatment. Am Fam Physician. 2015;92(3):187–96.PubMedGoogle Scholar
  5. 5.
    Harper J, Del Rosso JQ, Ferrusi IL. Cross-sectional survey of the burden of illness of rosacea by erythema severity. J Drugs Dermatol. 2018;17(2):150–8.PubMedGoogle Scholar
  6. 6.
    Zeichner JA, Eichenfield L, Feldman SR, et al. Quality of life in individuals with erythematotelangiectatic and papulopustular rosacea: findings from a web-based survey. J Clin Aesthet Dermatol. 2018;11(2):47–52.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Rhofade™ (oxymetazoline hydrochloride) cream, for topical use: US prescribing information. Accessed 12 Nov 2018.
  8. 8.
    Kuang AW, DuBois J, Attar M, et al. Clinical pharmacokinetics of oxymetazoline cream following topical facial administration for the treatment of erythema associated with rosacea. J Drugs Dermatol. 2018;17(2):213–20.PubMedGoogle Scholar
  9. 9.
    Del Rosso JQ. Topical α-agonist therapy for persistent facial erythema of rosacea and the addition of oxmetazoline to the treatment armamentarium: where are we now? J Clin Aesthet Dermatol. 2017;10(7):28–32.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Del Rosso JQ. Management of cutaneous rosacea: emphasis on new medical therapies. Expert Opin Pharmacother. 2014;15(14):2029–38.CrossRefPubMedGoogle Scholar
  11. 11.
    Piwnica D, Pathak A, Schafer G, et al. In vitro safety pharmacology profiling of topical α-adrenergic agonist treatments for erythema of rosacea. Drugs R D. 2018;18(1):87–90.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hsia E, Tian M, Gil D. Reduction in ultraviolet B light-induced erythema by oxymetazoline and brimonidine is mediated by different α-adrenoceptors. Exp Dermatol. 2018;27(7):763–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Mirvaso® (brimonidine) topical gel, 0.33%: US prescribing information. Fort Worth (TX): Galderma Laboratories; 2017.Google Scholar
  14. 14.
    Tian M, Hsia E, Andrews-Jones L, et al. The alpha adrenergic receptor agonist oxymetazoline decreases erythema and inflammation in a UVB-induced sunburn model [abstract no. 1251]. J Invest Dermatol. 2013;133(Suppl 1):S213.Google Scholar
  15. 15.
    Hsia E, Tian M, Santori E, et al. The alpha adrenergic receptor agonist oxymetazoline inhibits temperature-induced vasodilation and LL-37-induced skin inflammation [abstract no. 021]. J Invest Dermatol. 2012;132(Suppl. 1):S4.Google Scholar
  16. 16.
    DuBois J, Dover JS, Jones TM, et al. Phase 2 randomized, dose-ranging study of oxymetazoline cream for treatment of persistent facial erythema associated with rosacea. J Drugs Dermatol. 2018;17(3):308–16.PubMedGoogle Scholar
  17. 17.
    Kircik LH, DuBois J, Draelos ZD, et al. Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the first REVEAL trial. J Drugs Dermatol. 2018;17(1):97–105.PubMedGoogle Scholar
  18. 18.
    Baumann L, Goldberg DJ, Stein-Gold L, et al. Pivotal trial of the efficacy and safey of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the second REVEAL trial. J Drugs Dermatol. 2018;17(3):290–8.PubMedGoogle Scholar
  19. 19.
    Stein-Gold L, Kircik LH, Draelos ZD, et al. Topical oxymetazoline cream 1.0% for persistent facial erythema associated with rosacea: pooled analysis of the two phase 3, 29-day, randomized, controlled REVEAL trials. J Am Acad Dermatol. 17(11):1201–8.Google Scholar
  20. 20.
    Tanghetti EA, Dover JS, Goldberg DJ, et al. Clinically relevant reduction in persistent facial erythema of rosacea on the first day of treatment with oxymetazoline cream 1.0. J Drugs Dermatol. 2018;17(6):621–6.PubMedGoogle Scholar
  21. 21.
    Draelos ZD, Gold MH, Weiss RA, et al. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 52-week open label REVEAL trial. J Am Acad Dermatol. 2018;78(6):1156–63.CrossRefPubMedGoogle Scholar
  22. 22.
    Gold MH, Lebwohl M, Biesman BS, et al. Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistant erythema of rosecea through 52 weeks of treatment [letter]. J Am Acad Dermatol. 79(3):e57–e59.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations